HOWL WEREWOLF THERAPEUTICS INC

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer and Randi Isaacs, M.D., Chief Medical Officer, both of Werewolf Therapeutics, will participate in a fireside chat at 4:20 PM EDT on Thursday, June 5, 2025, at the Jefferies Global Healthcare Conference, taking place on June 3-5, 2025.

A live webcast link for the presentation will be available at . An archived replay will be available for approximately 90 days following the event.

About Werewolf Therapeutics:

Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company is leveraging its proprietary PREDATOR® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 in multiple tumor types or Non-Hodgkin Lymphoma as a single agent. To learn more visit

WEREWOLF®, the WEREWOLF logo, PREDATOR®, INDUKINE and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.



Investor Contact

Dan Ferry
LifeSci Advisors
617.430.7576
 

Media Contact:

Amanda Sellers
Deerfield Group
301.332.5574
 

Company Contact:
Timothy Trost
Chief Financial Officer
Werewolf Therapeutics
 
EN
29/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on WEREWOLF THERAPEUTICS INC

 PRESS RELEASE

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global ...

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer and Randi Isaacs, M.D., Chief Medical Officer, both of Werewolf Therapeutics, will participate in a fireside...

 PRESS RELEASE

HonorHealth Research Institute patient with advanced skin cancer in re...

HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124 There are nearly 40,000 U.S. cases of cutaneous squamous cell carcinoma each year that advance to stages that are difficult to treat and life-threatening Skin Cancer Awareness Month in May shines a spotlight on the growing burden of advanced skin cancers The investigational drug is designed to be activated in the tumor microenvironment, including in cutaneous squamous cell ...

 PRESS RELEASE

Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytok...

Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced Sameer Chopra, M.D., Ph.D., Vice President of Clinical Development, will speak during the Hanson Wade Cytokine-Based Drug Develo...

Ritika Das ... (+2)
  • Ritika Das
  • Robert Driscoll

ResearchPool Subscriptions

Get the most out of your insights

Get in touch